Equities

Remedis SA

REM:WSE

Remedis SA

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (PLN)0.08
  • Today's Change0.00 / 0.00%
  • Shares traded12.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 07 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

REMEDIS SA is a Poland-based company principally engaged in the financial services provision. Its offer includes financial restructuring services, loan provision, creation of business analysis and restructuring programs, credit intermediation, factoring, as well as receivables purchase and debt collection. The Company's main clients are the Polish health care facilities and local government units. As of December 31, 2011 KLN Investments Sp. z o.o. held an 88% stake in REMEDIS SA. On April 2011, the Company merged with Inwest Consulting SA.

  • Revenue in PLN (TTM)59.96k
  • Net income in PLN-2.47m
  • Incorporated2006
  • Employees2.00
  • Location
    Remedis SAul. Petera Mansfelda 4POZNAN 60-855PolandPOL
  • Phone+48 616657800
  • Fax+48 616657809
  • Websitehttp://remedis.eu/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fast Finance SA1.32m7.30m1.26m25.00----0.1590.95475.845.841.060.26420.7027--2.66--388.04-67.12----100.0183.19552.21-276.22----0.00---67.98-40.685,265.4928.79----
Investment Friends SE146.83k43.19k1.58m0.00238.340.2569--10.790.00160.00160.00271.520.0231------0.6798--0.703------29.41----6.000.00---3.33--13.24------
REMEDIS SA59.96k-2.47m5.06m2.00------84.46-0.039-0.0390.0010.0040.006--0.1033---24.82-9.47-155.58-17.8098.8242.25-4,122.45-381.78---0.55930.9714---17.47-43.13-259.12------
Wierzyciel SA2.42m-469.89k7.68m9.00--1.01--3.17-0.0624-0.06240.32171.010.2923--0.4772---5.67-5.75-6.01-5.8999.2598.53-19.40-40.579.84--0.00--62.805.0840.04---29.23--
Notoria SA3.72m386.14k9.48m10.0024.554.038.362.550.32180.32183.101.961.07--7.89--11.1010.9914.8614.3479.1198.1710.3810.23----0.00125.2712.146.09-12.2212.0317.89--
MW Trade SA444.00k-2.79m9.80m8.00--0.3896--22.08-1.09-1.090.17399.860.0155-------11.72-2.14-12.32-2.4896.6240.25-754.28-51.92----0.0227---44.58-51.90-28.60--72.21--
Npl Nova SA4.35m-1.04m14.02m94.00--0.6327--3.23-0.2817-0.28171.186.020.0592--11.77---1.41-3.92-4.08-6.09-----23.84-44.70---0.10550.0937---11.50-37.6647.55---64.27--
Kancelaria Medius SA16.55m-1.61m16.17m41.00------0.9774-0.1106-0.11061.13-3.840.3602--73.22---3.51-3.56---5.34-----9.74-24.29--0.63754.40--20.22-21.10170.18-32.24-59.74--
DGA SA-100.00bn-100.00bn20.12m21.00--1.13----------15.74----------3.00--5.04--13.52--10.52----0.001734.8625.384.20-95.78-43.97-34.22-11.81
Analizy Online SA12.08m1.92m23.84m--12.417.009.001.971.601.6010.092.841.934.5611.35--30.6712.0854.6014.3298.9398.5115.906.551.81--0.0301174.5213.4110.4438.203.95-20.06--
Data as of Aug 07 2023. Currency figures normalised to Remedis SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.